Cornell University researchers developed an oxygenated macroencapsulation system named BEAM that enables high-density transplant and survival of insulin-producing cells without immunosuppression in type 1 diabetes models. Published in Nature Communications, this technology addresses the critical challenge of oxygen deprivation in implanted cell therapies. The system improves longevity and function of encapsulated pancreatic beta cells, representing a potential transformative advance toward curative cell replacement therapies for diabetes.